

Brilliant Violet 421™ anti-human CD25 Antibody

Catalog# / Size	302629 / 25 tests 302630 / 100 tests
Clone	BC96
Regulatory Status	RUO
Workshop	V T-072
Other Names	Low affinity IL-2R, IL-2R α chain, Tac, p55
Isotype	Mouse IgG1, κ
Description	CD25 is a 55 kD type I transmembrane glycoprotein also known as the low affinity IL-2 receptor α chain or Tac. It is expressed on progenitor lymphocytes, activated T and B cells, and activated monocytes/macrophages. CD25 is also expressed on a subset of non-stimulated CD4 ⁺ T cells termed T regulatory cells. CD25 associates with the IL-2 receptor β (CD122) and common γ chains (CD132) to form the high affinity IL-2R complex.

Product Details

Verified Reactivity	Human
Reported Reactivity	Baboon, Chimpanzee, Cynomolgus, Pigtailed Macaque, Rhesus
Antibody Type	Monoclonal
Host Species	Mouse
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration	Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is 5 μ l per million cells in 100 μ l staining volume or 5 μ l per 100 μ l of whole blood. Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser	Violet Laser (405 nm)
Application Notes	Additional reported applications include: immunocytochemistry ³ .
Additional Product Notes	View more applications data for this product in our Scientific Poster Library .
Application References	1. Schlossman S, <i>et al.</i> Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.

(PubMed link indicates BioLegend citation)

2. Kmiecik M, *et al.* 2009. *J. Transl. Med.* 7:89. (FC) [PubMed](#)
3. Ernst CW, *et al.* 2007. *Clin. Exp. Immunol.* 148:271. (ICC) [PubMed](#)

Product Citations

1. Marco Barros R, *et al.* 2016. *Cell.* 167: 203-218. [PubMed](#)
2. Shoda H, *et al.* 2017. *Arthritis Research & Therapy* . 10.1186/s13075-017-1308-y. [PubMed](#)
3. Nagafuchi Y, *et al.* 2016. *Sci Rep.* 6:29338. [PubMed](#)
4. van der Heiden M, *et al.* 2020. *Scand J Immunol.* e13005:. [PubMed](#)
5. Nesspor TC, *et al.* 2020. *Sci Rep.* 10:7557. [PubMed](#)
6. Huang C, *et al.* 2020. *Theranostics.* 10:10498. [PubMed](#)
7. Pan YG, *et al.* 2021. *Immunity.* 54(6):1245-1256.e5. [PubMed](#)
8. Torres-Ruiz J, *et al.* 2021. *Front Immunol.* 12:689966. [PubMed](#)
9. Herter JM, *et al.* 2022. *Strahlenther Onkol.* Online ahead of print. [PubMed](#)
10. Lam AJ, *et al.* 2021. *Cell Reports.* 36(5):109494. [PubMed](#)
11. Jürchott K, *et al.* 2016. *PLoS One.* 11: 0150812. [PubMed](#)
12. Pagel J, *et al.* 2020. *Front Immunol.* 11:565257. [PubMed](#)
13. Idorn M, *et al.* 2018. *Oncoimmunology.* 7:e1412029. [PubMed](#)
14. Yang L, *et al.* 2020. *Genes Dis.* 7:128. [PubMed](#)
15. Ellis GI, *et al.* 2022. *STAR Protoc.* 3:101784. [PubMed](#)
16. Nowak A, *et al.* 2018. *Front Immunol.* 0.513194444. [PubMed](#)
17. Nakachi S, *et al.* 2017. *Arthritis Research & Therapy* . 10.1186/s13075-017-1309-x. [PubMed](#)
18. Gao X, *et al.* 2022. *iScience.* 25:104911. [PubMed](#)
19. Nguyen J, *et al.* 2021. *Mol Syst Biol.* 17:e10560. [PubMed](#)
20. Paul S, *et al.* 2021. *Sci Transl Med.* 13:. [PubMed](#)
21. Hernandez DC, *et al.* 2021. *Immunity.* .: [PubMed](#)
22. Janssen JJE, *et al.* 2022. *Am J Physiol Endocrinol Metab.* 322:E141. [PubMed](#)
23. Pandya J, *et al.* 2016. *J Leukoc Biol.* 100: 823 - 833. [PubMed](#)
24. Manuszak C, *et al.* 2020. *J Biol Methods.* 7:e131. [PubMed](#)
25. Li H, *et al.* 2020. *Front Oncol.* 1.477083333. [PubMed](#)
26. Nowatzky J, *et al.* 2020. *J Vis Exp.* . [PubMed](#)
27. Fu J, *et al.* 2021. *J Clin Invest.* 131:. [PubMed](#)
28. Lin-Shiao E, *et al.* 2022. *Nucleic Acids Res.* 50:1256. [PubMed](#)

RRID

AB_10896914 (BioLegend Cat. No. 302629)
AB_11126749 (BioLegend Cat. No. 302630)

Antigen Details

Structure	Type I transmembrane glycoprotein, 55 kD
Distribution	Activated T cells and B cells, monocytes/macrophages, Treg
Function	Associates with IL-2 receptor β (CD122) and γ chains (CD132) to form high affinity IL-2R complex
Ligand/Receptor	IL-2
Cell Type	B cells, Macrophages, Monocytes, T cells, Tregs
Biology Area	Cell Biology, Immunology, Neuroscience, Neuroscience Cell Markers
Molecular Family	CD Molecules, Cytokine/Chemokine Receptors
Antigen References	1. Taniguchi T, <i>et al.</i> 1993. <i>Cell</i> 73:5. 2. Waldmann T. 1991. <i>J. Biol. Chem.</i> 266:2681.
Gene ID	3559

Related Protocols


[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-human CD25, FITC anti-human CD25, PE anti-human CD25, PE/Cyanine5 anti-human CD25, Purified anti-human CD25, APC/Cyanine7 anti-human CD25, PE/Cyanine7 anti-human CD25, Alexa Fluor® 488 anti-human CD25, Alexa Fluor® 647 anti-human CD25, Pacific Blue™ anti-human CD25, Alexa Fluor® 700 anti-human CD25, Biotin anti-human CD25, PerCP/Cyanine5.5 anti-human CD25, Brilliant Violet 421™ anti-human CD25, Brilliant Violet 605™ anti-human CD25, Brilliant Violet 650™ anti-human CD25, Brilliant Violet 711™ anti-human CD25, Brilliant Violet 785™ anti-human CD25, Brilliant Violet 510™ anti-human CD25,

APC/Fire™ 750 anti-human CD25, TotalSeq™-A0085 anti-human CD25, PE/Dazzle™ 594 anti-human CD25, TotalSeq™-B0085 anti-human CD25, TotalSeq™-C0085 anti-human CD25, TotalSeq™-D0085 anti-human CD25

Product Data



Human peripheral blood lymphocytes were stained with CD4 FITC and CD25 (clone BC96) Brilliant Violet 421™ (top) or mouse IgG1, κ Brilliant Violet 421™ isotype control (bottom).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587